Karin Eastham sold $909k of VCYT
director at VERACYTE, INC.. 20,000 shares at an average of $45.45, traded Dec 5, 2025, filed Dec 8, 2025.
Score components
- +15RoleDirector
- +24Trade size$909k at market
- +20Share of holdings soldSold 60% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +1.7%, 3m -24.8%, 6m +6.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231845-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | MOption exercise Common Stock10b5-1 | +10,000 | $7.94 | $79k | 23,554 | Dec 8, 2025 |
| Dec 5, 2025 | MOption exercise Common Stock10b5-1 | +10,000 | $7.60 | $76k | 33,554 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock10b5-1 | -6,392 | $44.52 | $285k | 27,162 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock10b5-1 | -12,808 | $45.84 | $587k | 14,354 | Dec 8, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock10b5-1 | -800 | $46.59 | $37k | 13,554 | Dec 8, 2025 |
| Dec 5, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Dec 8, 2025 |
| Dec 5, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Dec 8, 2025 |
Related signals
Other insiders at VERACYTE, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | VERACYTE, INC. | John Leite Global Chief Commercial Off | $161k 4,015 shares | -3% | |
| 27Weak | VERACYTE, INC. | Jens Holstein director | $205k 5,000 shares | -15% | |
| 28Weak | VERACYTE, INC. | Rebecca Chambers Chief Financial Officer | $157k 3,652 shares | -2% | |
| 29Weak | VERACYTE, INC. | Phillip G. Febbo Chief Scientific & Med Officer | $564k 13,110 shares | -9% | |
| 21Weak | VERACYTE, INC. | Annie McGuire EVP, General Counsel | $140k 3,254 shares | -2% | |
| 19Weak | VERACYTE, INC. | Muna Bhanji director | $80k 1,864 shares | -4% | |
| 27Weak | VERACYTE, INC. | Karin Eastham director | $197k 3,729 shares | -20% | |
| 29Weak | VERACYTE, INC. | Rebecca Chambers Chief Financial Officer | $177k 3,561 shares | -2% | |
| 31Weak | VERACYTE, INC. | John Leite Global Chief Commercial Off | $700k 13,975 shares | -10% | |
| 21Weak | VERACYTE, INC. | Annie McGuire EVP, General Counsel | $158k 3,176 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.